Anticoagulation after cardioembolic stroke: To bridge or not to bridge?

Archives of Neurology

Volumn 65, Issue 9, 2008, Pages 1169-1173

  Hallevi, Hen ^a   Albright, Karen C ^c   Martin Schild, Sheryl ^a   Barreto, Andrew D ^a   Savitz, Sean I ^a   Escobar, Miguel A ^b   Gonzales, Nicole R ^a   Noser, Elizabeth A ^a   Illoh, Kachi ^a   Grotta, James C ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMATOMA; CARDIOEMBOLIC STROKE; DISEASE CLASSIFICATION; DISEASE COURSE; FEMALE; HEMATOMA; HOSPITAL DISCHARGE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; OUTCOME ASSESSMENT; PARENCHYMAL HEMATOMA; PRIORITY JOURNAL; PROGRESSIVE STROKE; RANKIN SCALE; RECURRENT STROKE; STROKE; SYSTEMIC BLEEDING;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; STROKE; TIME FACTORS;

EID: 51649106812     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.65.9.noc70105     Document Type: Article

References (15)

1. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation: the Copenhagen Stroke Study. Stroke. 1996;27(10):1765-1769.
2. Kelley RE, Berger JR, Alter M, Kovacs AG. Cerebral ischemia and atrial fibrillation: prospective study. Neurology. 1984;34(10):1285-1291.
3. Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38(5):1655-1711.
4. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 2007;38(2):423-430.
5. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke. 1999;30(11):2280-2284.
6. Viganò S, Mannucci PM, Solinas S, Bottasso B, Mariani G. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol. 1984;57(2):213-220.
7. Sternberg ML, Pettyjohn FS. Warfarin sodium-induced skin necrosis. Ann Emerg Med. 1995;26(1):94-97.
8. Zeuthen EL, Lassen JF, Husted SE. Is there a hypercoagulable phase during initiation of antithrombotic therapy with oral anticoagulants in patients with atrial fibrillation? Thromb Res. 2003;109(5-6):241-246.
9. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [published correction appears in Chest. 2005;127(1):415-416]. Chest. 2004;126(3)(suppl):204S-233S.
10. de Courten-Myers GM, Kleinholz M, Holm P, et al. Hemorrhagic infarct conversion in experimental stroke. Ann Emerg Med. 1992;21(2):120-126.
11. Berge E, Abdelnoor M, Nakstad PH, Sandset PM; HAEST Study Group. Low molecular-weight heparin vs aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. Lancet. 2000;355(9211):1205-1210.
12. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349(9065):1569-1581.
13. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J. Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS) I. Stroke. 1999;30(12):2631-2636.
14. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36(11):2415-2420.
15. Chamorro A, Vila N, Ascaso C, Blanc R. Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. Arch Neurol. 1999;56(9):1098-1102.